NASDAQ : INAB
IN8bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.9801 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.89M |
| Enterprise Value | -6.89M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +405.26% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 3.17% |
| Owned by Institutions (%) | 19.24% |
| Float | 7.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.21 |
| Quick Ratio | 7.97 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -111.11% |
| Return on Assets (ROA) | -58.37% |
| Return on Invested Capital (ROIC) | -61.70% |
| Return on Capital Employed (ROCE) | -98.51% |
| Weighted Average Cost of Capital (WACC) | 4.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -54.94% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 33.69 |
| Average Volume (20 Days) | 39,854 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 32,797 |
| Short Previous Month | 46,440 |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.46% |
| Short Ratio (days to cover) | 0.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.20M |
| Pretax Income | -18.67M |
| Net Income | -18.67M |
| EBITDA | -17.80M |
| EBIT | -19.20M |
| Earnings Per Share (EPS) | -$1.48 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 17.96M |
| Total Debt | 2.18M |
| Net Cash | 15.78M |
| Net Cash Per Share | $1.60 |
| Equity (Book Value) | 18.36M |
| Book Value Per Share | 1.86 |
| Working Capital | 16.24M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -14.36M |
| Capital Expenditures | -242,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -403,000 |
| Free Cash Flow | -14.60M |
| FCF Per Share | -$1.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -405.26% |
| Shareholder Yield | -405.26% |
| Earnings Yield | -163.75% |
| FCF Yield | -164.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.00 |
| Price Target Difference | 676.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 6, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |